** Morgan Stanley stars coverage on Celldex Therapeutics CLDX.O with "overweight" rating and PT of $46, citing the co's "pipeline potential in alternative mast cell-mediated diseases" and a "risk/reward that is skewed to the upside"
** PT represents a 130.7% upside to stock's last close
** Says co's lead skin disease drug, barzolvolimab, has shown a "potentially market-leading efficacy profile" in chronic urticaria, a condition with "significant unmet need" and limited treatment options
** Expects barzolvolimab to generate $1.3 bln in risk-adjusted revenue by 2035, modestly below consensus estimates, due to competition from other therapies
** Despite competition, barzolvolimab has a "unique ability to deplete mast cells", which could give it an edge in treating most cell-mediated diseases - brokerage
** CLDX fell 50.7% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。